Lenti-HPV-07 immunotherapy for HPV throat or cervical cancer
Part of Cancer, Ear, nose & throat, Mouth & dental, Women’s health & pregnancy clinical trials.
This trial tests a new immunotherapy called Lenti-HPV-07 for people with HPV-related throat or cervical cancer. It aims to help your immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cancer caused by HPV, either in the throat (oropharynx) or cervix.
- You should be well enough to take care of yourself (ECOG score 0 or 1).
- Your liver, kidneys, lungs, and blood counts must be within a healthy range.
- You cannot have HIV, active hepatitis B, or active hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new nasal vaccine combined with an immunotherapy drug (tislelizumab) given before surgery for people with HPV-positive oropharyngeal cancer. The goal is to help the immune system fight the cancer and potentially improve outcomes after surgery.
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
This trial tests whether using a de-escalated (lower/intensity-reduced) radiation approach can treat HPV-positive oropharyngeal squamous cell carcinoma. It may help reduce side effects while still keeping the cancer under control.
This study checks a blood test that looks for HPV tumor DNA to help doctors decide when to start routine treatment after surgery. It may help some people avoid starting treatment too early or too late based on how the test changes after the operation.
This trial tests an investigational vaccine called BVAC-E6E7 for head and neck cancer caused by HPV types 16 or 18 that has come back or spread. It is for people who have already tried standard treatments like platinum chemo or immunotherapy, or can't take them.
Hear when a new HPV-Related Cervical Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.